Recap: Revance Therapeutics Q3 Earnings

Shares of Revance Therapeutics RVNC decreased 8.62% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 39.58% year over year to ($1.34), which missed the estimate of ($1.03).

Revenue of $3,835,000 up by 8236.96% from the same period last year, which beat the estimate of $1,780,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revance Therapeutics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 09, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/tdbm83r6

Recent Stock Performance

Company's 52-week high was at $34.62

52-week low: $11.78

Price action over last quarter: down 3.22%

Company Profile

Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables the delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications.